The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Improving population-tailored immunotherapy: implications from a Mediterranean cohort study
Osama Alsmadi, PhD, King Hussein Cancer Center, Amman, Jordan, discusses ways to improve population-tailored immunotherapy for underrepresented Mediterranean populations, highlighting the need for prospective clinical trials to ensure equity in healthcare and inclusivity. Dr Alsmadi emphasizes the importance of genomic database research and international collaborations. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
